VWR Corporation (VWR) Downgraded by ValuEngine to “Hold”

VWR Corporation (NASDAQ:VWR) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

Several other research analysts also recently weighed in on VWR. BidaskClub raised shares of VWR Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, August 11th. Zacks Investment Research raised shares of VWR Corporation from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. VWR Corporation presently has an average rating of “Hold” and an average price target of $31.67.

Shares of VWR Corporation (NASDAQ VWR) opened at 33.07 on Wednesday. The company has a 50 day moving average price of $33.11 and a 200-day moving average price of $32.07. The stock has a market cap of $4.36 billion, a P/E ratio of 30.62 and a beta of 1.18. VWR Corporation has a 12 month low of $24.42 and a 12 month high of $37.25.

VWR Corporation (NASDAQ:VWR) last issued its earnings results on Monday, July 31st. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.04. The company had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.16 billion. VWR Corporation had a net margin of 3.12% and a return on equity of 15.54%. VWR Corporation’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.42 EPS. On average, equities research analysts predict that VWR Corporation will post $1.86 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2017/10/11/vwr-corporation-vwr-downgraded-by-valuengine-to-hold.html.

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in VWR Corporation in the 2nd quarter worth $531,000. Earnest Partners LLC boosted its holdings in VWR Corporation by 116.8% in the 1st quarter. Earnest Partners LLC now owns 1,797,102 shares of the medical research company’s stock worth $50,678,000 after buying an additional 968,313 shares during the period. Vanguard Group Inc. boosted its holdings in VWR Corporation by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 6,827,046 shares of the medical research company’s stock worth $192,523,000 after buying an additional 345,117 shares during the period. Ameriprise Financial Inc. boosted its holdings in VWR Corporation by 7.3% in the 1st quarter. Ameriprise Financial Inc. now owns 49,824 shares of the medical research company’s stock worth $1,405,000 after buying an additional 3,374 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its holdings in VWR Corporation by 9.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 406,257 shares of the medical research company’s stock worth $11,457,000 after buying an additional 36,516 shares during the period.

VWR Corporation Company Profile

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.

Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply